Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AP301, a novel iron-based phosphate binder, in patients with chronic kidney disease who are receiving maintenance dialysis and have elevated blood phosphate levels. This phase 3, randomized, double-blind study aims to determine whether AP301 lowers blood phosphate and how it affects serum calcium, calcium times phosphate, and intact parathyroid hormone levels. The trial also assesses any discomfort or medical problems during treatment and its impact on quality of life in Chinese patients. Participants will first stop all phosphate-lowering medications. They will then take either AP301 or a low-dose comparator considered ineffective three times daily for 8 weeks. Following this, all participants receive AP301 three times daily for 24 weeks, with dose adjustments based on blood phosphate levels and physician judgment. Finally, participants will take either AP301 or the comparator three times daily for 3 weeks. Additional treatments may be given if blood phosphate levels become too high or low. During the study, participants will undergo regular assessments including blood tests to monitor serum phosphate, calcium, and parathyroid hormone levels. Electrocardiogram tests will measure changes in QT intervals. Safety is monitored by tracking adverse events throughout the trial, which lasts up to 37 weeks. The primary outcome is the change in serum phosphate concentration from baseline to the end of week 8, with ongoing evaluations over the entire study period.
Actively Recruiting
Researchers are evaluating the safety and efficacy of intravesical nadofaragene firadenovec alone or combined with chemotherapy or immunotherapy in participants with high-grade Bacillus Calmette-Guerin BCG unresponsive non-muscle invasive bladder cancer NMIBC with carcinoma in situ CIS high-grade TaT1. This pivotal phase 3 trial builds on prior findings where 53.4% of subjects achieved a complete response at 3 months, aiming to offer new options for patients unlikely to benefit from further BCG treatment. Participants are randomly assigned to one of two study groups nadofaragene firadenovec alone or nadofaragene firadenovec combined with sequential intravesical gemcitabine and docetaxel chemotherapy. The trial originally included a third arm with pembrolizumab infusion, but this arm is closed to new participants. Treatment involves intravesical bladder instillation of the study drugs, with pembrolizumab delivered by intravenous infusion for patients already enrolled in that arm. During the study, participants undergo regular assessments including evaluations of complete response at 3 and 6 months, durability of response up to 24 months, monitoring for disease progression, cystectomy-free survival, pathological staging, and overall survival up to 36 months. Safety is monitored through adverse event tracking. Participants are expected to be available for the entire study duration, which extends to 2030, allowing long-term observation of treatment effects and disease status.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Steerable Ureteroscopic Renal Evacuation SURE using the CVAC System compared to other common treatments for kidney stones. This prospective, observational trial involves up to 250 participants across approximately 25 sites, focusing on patients undergoing procedures for renal stones such as ureteroscopy or percutaneous nephrolithotomy. The study aims to understand how well these different techniques clear kidney stones and assess their safety. Participants will receive one of several kidney stone removal interventions, including the CVAC System, Flexible and Navigational Ureteral Access Sheath FANS, Direct In-Scope Suction DISS, standard ureteroscopy without suction, or percutaneous nephrolithotomy PCNL. These procedures involve various methods such as laser fragmentation, suction-assisted stone removal, and surgical extraction under anesthesia. Each technique uses specialized devices or methods to visualize and remove kidney stones during treatment. Throughout the study, participants will be monitored and evaluated with follow-up visits to assess outcomes such as residual stone volume 30 days after treatment. Researchers will collect data on stone clearance effectiveness and any safety concerns. Participants will be expected to attend all follow-up procedures and respond to study assessments, with the trial lasting until the study completion date in late 2029.
Actively Recruiting
Researchers are conducting a phase 3b randomized, controlled trial to compare nadofaragene firadenovec versus observation in participants with intermediate risk non-muscle invasive bladder cancer IR NMIBC. The study aims to evaluate treatment effects on recurrence-free survival over a 24-month period. This trial is sponsored by Ferring Pharmaceuticals and focuses on participants who have undergone prior tumor resection and meet specific risk criteria according to established urological guidelines. Participants assigned to the nadofaragene firadenovec group will receive quarterly instillations of this vector-based gene therapy designed to boost the bodys interferon alfa-2b response for up to 24 months. Those in the observation group will be followed according to routine surveillance schedules recommended by the American Urological Association AUA and the Society of Urologic Oncology SUO, also on a quarterly basis for 24 months. Disease evaluations for treated participants will occur within two weeks prior to each treatment instillation. Throughout the study, participants will undergo regular disease evaluations and monitoring for adverse events up to 24 months. Researchers will measure recurrence-free survival at 12 and 24 months as primary and secondary outcomes. The trial design includes randomized allocation without masking, and participants will be followed during the treatment period and beyond for safety and efficacy assessments, with total participation lasting up to 24 months.